Trials / Completed
CompletedNCT00724334
A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis
An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.
Detailed description
SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety, tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAR302503 (TG101348) | orally administered, once a day |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2008-07-29
- Last updated
- 2025-03-05
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00724334. Inclusion in this directory is not an endorsement.